Tesi

Hadean Ventures announces oversubscribed final close of Hadean Capital II - a fund dedicated to investments in life science start-ups across Europe

Retrieved on: 
Thursday, December 21, 2023
Ecosystem, Acquisition, Eli Lilly, Tesi, Therapy, Venture, Growth, EUR, Capital, Investment, Emergence, Partner (business rank), Environment, Cryptocurrency

Hadean Capital II closes at EUR 144m, substantially over target of EUR 125m, bringing the total committed capital of Hadean Ventures' two funds to approx.

Key Points: 
  • Hadean Capital II closes at EUR 144m, substantially over target of EUR 125m, bringing the total committed capital of Hadean Ventures' two funds to approx.
  • The fund will invest in life science start-up companies across Europe with an emphasis on the Nordics and German-speaking countries.
  • Key investors in Hadean Capital II shared their comments:
    "Saminvest is very excited to be one of the founding investors of Hadean Ventures.
  • We are thrilled to be part of the closing of Hadean Capital II, contributing to the growth of the Norwegian and European life science ecosystem.

Hadean Ventures announces oversubscribed final close of Hadean Capital II - a fund dedicated to investments in life science start-ups across Europe

Retrieved on: 
Thursday, December 21, 2023
Ecosystem, Acquisition, Eli Lilly, Tesi, Therapy, Venture, Growth, EUR, Capital, Investment, Emergence, Partner (business rank), Environment, Cryptocurrency

Hadean Capital II closes at EUR 144m, substantially over target of EUR 125m, bringing the total committed capital of Hadean Ventures' two funds to approx.

Key Points: 
  • Hadean Capital II closes at EUR 144m, substantially over target of EUR 125m, bringing the total committed capital of Hadean Ventures' two funds to approx.
  • The fund will invest in life science start-up companies across Europe with an emphasis on the Nordics and German-speaking countries.
  • Key investors in Hadean Capital II shared their comments:
    "Saminvest is very excited to be one of the founding investors of Hadean Ventures.
  • We are thrilled to be part of the closing of Hadean Capital II, contributing to the growth of the Norwegian and European life science ecosystem.

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Thursday, September 7, 2023
InterContinental New York Barclay Hotel, Tesi, Lotte New York Palace Hotel, Hotel

Dr Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference.

Key Points: 
  • Dr Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference.
  • The conference is being held September 12 -13, 2023 at the InterContinental New York Barclay.
  • To register for the conference, click here :
    Dr Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference.
  • To request a meeting and to register for the conference, click here .

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

Retrieved on: 
Wednesday, July 12, 2023
Heart, Obesity, Drug development, Diet, Rejuvenation, Apolipoprotein E, Prevalence, Life, Diabetes, Inflammaging, Albert Einstein's brain, Overalls, DSM-IV codes, Quality of life, Cross, Brain, Research, Inflammation, Biomarker, Autoimmunity, Trial of the century, Cellular senescence, Literature, Pesticide, Aging brain, MD, Patient, Tesi, Conditional sentence, Health, AD, Smoking, Conference, Foundation for the National Institutes of Health, Neuroinflammation, Disease, Medical imaging, Ageing

Boca Raton, Florida, July 12, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023.

Key Points: 
  • Chronic diseases of aging affect virtually every organ system, including the heart, brain, eyes, ears, bones, and skeletal muscles.
  • Unfortunately, they contribute to a diminished health span, resulting in shortened life spans, increased elder care costs, and reduced quality of life.
  • “Cognitive aging is a well-defined disease that has not been the subject of extensive clinical study or intervention,” said CJ Barnum, VP CNS Development at INmune Bio.
  • Unfortunately, no treatments currently exist for inflammaging.”
    “The field of aging research and drug development has many challenges,” said RJ Tesi, MD, CEO of INmune Bio said.

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

Retrieved on: 
Wednesday, May 24, 2023
ICST, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, IL15, Failure, Gene, Prostate cancer, Half-life, ISCT, NK, Toxicity, Research, Cell, Protein, Cytokine, Cytokine release syndrome, Patient, Manuscript, Risk, Tesi, TME, Interleukin, UCLA, Urology, Phase, Phenotype, IND, Natural killer T cell, Memory, Safety, International Society, Vaccine, Cancer, List of things named after Thomas Bayes, Medicine

The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.

Key Points: 
  • The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.
  • Using high-dimensional flow cytometry to simultaneously analyze 31 cell surface proteins, the team analyzed resting NK cells, IL-15 LAK (LAK=lymphokine activated killer cells), CIML-NK and INKmune-primed (TpNK) side-by-side.
  • The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK.
  • CIML-NK contains a large population of terminally activated cells with loss of spare respiratory activity, which is absent from TpNK.

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, May 8, 2023
David Geffen School of Medicine at UCLA, DNA, CT, Jonsson Comprehensive Cancer Center, PMSA, Prostate cancer, Progression-free survival, CSO, Clinical trial, Cancer, NK, Cell, Biomarker, Immunotherapy, Doctor of Philosophy, Trial of the century, MDS, Investigational New Drug, MD, Tesi, Patient, Blood, Toxic epidermal necrolysis, Neoplasm, UCLA, FDA, Prostate, Urology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, PSA, Food, Safety, Pharmaceutical industry, Medical imaging, Medicine

BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).

Key Points: 
  • BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.
  • The trial is expected to enroll the first of 30 patients in the second half of 2023.
  • The first trial, called Laurel, is an on-going Phase I trial in patients with high risk MDS or AML.

Nosto raises $16M as it launches site search within its Commerce Experience Platform (CXP)

Retrieved on: 
Thursday, February 23, 2023
Tesi, Shopify, GMV, Acquisition, Research, GE, Growth capital, CXP, Investment, Wellington Partners, Growth, Kylie Cosmetics, Princess, MAM, Natural language processing, Retail, Online shopping, Nostos: The Return, Nordic

NEW YORK, Feb. 23, 2023 /PRNewswire-PRWeb/ -- Nosto, the world's leading Commerce Experience Platform (CXP), has today announced the closure of its latest funding round of $16M USD, from Mandatum Asset Management's Growth Equity team (MAM GE).Already backed by OpenOcean, Wellington Partners, Eurazeo, and Tesi among others, the latest round from MAM GE accelerates Nosto's mission to make every impression relevant.

Key Points: 
  • "Merchants using Nosto are growing quickly, and merchants using Nosto on the Shopify platform are growing quicker still.
  • This investment will help us continue scaling our Commerce Experience Platform, supporting brands in their own growth ambitions.
  • "Since launching site search natively within our CXP , we're uniquely positioned to disrupt the product discovery space.
  • "This raise allows us to accelerate our innovation and continue developing our Commerce Experience Platform.